Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

VEGFA Antikörper

Rockland 209-401-c23 VEGFA Reaktivität: Human WB, ELISA Wirt: Kaninchen Polyclonal unconjugated
Rockland
Produktnummer ABIN964762
Hersteller Produkt- Nr.: 209-401-c23
  • Target Alle VEGFA Antikörper anzeigen
    VEGFA (Vascular Endothelial Growth Factor A (VEGFA))
    Reaktivität
    • 147
    • 101
    • 74
    • 22
    • 18
    • 17
    • 16
    • 10
    • 5
    • 5
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Wirt
    • 180
    • 56
    • 12
    • 1
    • 1
    • 1
    Kaninchen
    Klonalität
    • 193
    • 57
    • 1
    Polyklonal
    Konjugat
    • 122
    • 38
    • 23
    • 10
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser VEGFA Antikörper ist unkonjugiert
    Applikation
    • 187
    • 88
    • 55
    • 41
    • 41
    • 27
    • 24
    • 22
    • 21
    • 16
    • 12
    • 11
    • 10
    • 9
    • 8
    • 7
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), ELISA
    Hersteller Produkt- Nr.
    209-401-c23
    Hersteller
    Rockland
    Verwendungszweck
    VEGF-121 Antibody
    Kreuzreaktivität (Details)
    This antibody is specific for human VEGFA-121 protein.
    Produktmerkmale
    Synonyms: rabbit anti-VEGF-121 antibody, rabbit anti-Vascular endothelial growth factor A-121 antibody, VEGF-A121 cytokine, Vascular permeability factor, VPF-121, VEGFA-121
    Aufreinigung
    This product is an IgG fraction antibody purified from monospecific antiserum by a multi-step process which includes delipidation, salt fractionation and ion exchange chromatography followed by extensive dialysis against the buffer stated above.
    Immunogen

    Immunogen: This IgG fraction antibody was prepared from rabbit antiserum after repeated immunizations with mature length recombinant human VEGFA-121 protein produced in E.coli.

    Immunogen Type: Recombinant Protein

    Isotyp
    IgG
    Top Product
    Discover our top product VEGFA Primärantikörper
  • Applikationshinweise

    Application Note: This purified antibody has been tested in western blotting and suitable for ELISA. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 14.7 Da in size corresponding to the mature human VEGFA-121 protein by western blotting in appropriate cell lysate or extract.

    Western Blot Dilution: 1:1000

    ELISA Dilution: 1:10,000

    Other: User Optimized

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution

    Reconstitution Volume: 100 μL

    Reconstitution Buffer: Restore with deionized water (or equivalent)

    Konzentration
    1.0 mg/mL
    Buffer

    Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

    Stabilizer: None

    Preservative: None
    Konservierungsmittel
    Without preservative
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
    Haltbarkeit
    6 months
  • Target
    VEGFA (Vascular Endothelial Growth Factor A (VEGFA))
    Andere Bezeichnung
    VEGFA (VEGFA Produkte)
    Hintergrund
    Background: Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth, vascular permeability, cell migration, and endothelial cell proliferation and growth, it may play a role in stimulating vasodilation via nitric oxide-dependent pathways and in inhibition of apoptosis. VEGF binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. VEGF121 is acidic, freely secreted, and widely expressed. This isoform is produced by alternative promoter usage and alternative initiation. It starts at an alternative upstream CUG codon and is post-translationally processed to produce the secreted VEGF peptide and a N-terminal peptide N-VEGF. The unprocessed protein and the N-VEGF peptide may localize to the nucleus, the endoplasmic reticulum and the Golgi or the extracellular matrix.
    Gen-ID
    7422, 6631029
    UniProt
    P15692-9
    Pathways
    RTK Signalweg, Glycosaminoglycan Metabolic Process, Regulation of Cell Size, Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Platelet-derived growth Factor Receptor Signaling, VEGFR1 Specific Signals, VEGF Signaling
Kundenservice